La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Guobang Pharma Croissance future
Future contrôle des critères 4/6
Guobang Pharma is forecast to grow earnings and revenue by 22.5% and 13.9% per annum respectively. EPS is expected to grow by 22.4% per annum. Return on equity is forecast to be 11.8% in 3 years.
Informations clés
22.5%
Taux de croissance des bénéfices
22.4%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 18.8% |
| Taux de croissance des recettes | 13.9% |
| Rendement futur des capitaux propres | 11.8% |
| Couverture par les analystes | Low |
| Dernière mise à jour | 15 May 2024 |
Mises à jour récentes de la croissance future
Pas de mise à jour
Recent updates
These 4 Measures Indicate That Guobang Pharma (SHSE:605507) Is Using Debt Extensively
Jul 24
Guobang Pharma Ltd. (SHSE:605507) Analysts Just Cut Their EPS Forecasts Substantially
May 21Fewer Investors Than Expected Jumping On Guobang Pharma Ltd. (SHSE:605507)
Apr 18We Think Guobang Pharma (SHSE:605507) Is Taking Some Risk With Its Debt
Mar 25Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 7,251 | 1,028 | N/A | 1,518 | 1 |
| 12/31/2025 | 7,521 | 1,120 | 908 | 1,365 | 2 |
| 12/31/2024 | 5,907 | 722 | 186 | 723 | 1 |
| 3/31/2024 | 5,278 | 617 | -495 | 227 | N/A |
| 12/31/2023 | 5,349 | 612 | -232 | 517 | N/A |
| 9/30/2023 | 5,661 | 689 | -466 | 416 | N/A |
| 6/30/2023 | 5,827 | 783 | -78 | 839 | N/A |
| 3/31/2023 | 5,955 | 915 | 276 | 1,159 | N/A |
| 12/31/2022 | 5,721 | 921 | 214 | 1,017 | N/A |
| 9/30/2022 | 5,405 | 906 | 15 | 486 | N/A |
| 6/30/2022 | 4,966 | 823 | -576 | -177 | N/A |
| 3/31/2022 | 4,539 | 721 | -497 | -126 | N/A |
| 12/31/2021 | 4,505 | 706 | -624 | -176 | N/A |
| 9/30/2021 | 4,273 | 694 | -481 | 39 | N/A |
| 6/30/2021 | 4,317 | 741 | -110 | 444 | N/A |
| 3/31/2021 | 4,449 | 834 | -59 | 612 | N/A |
| 12/31/2020 | 4,206 | 810 | 246 | 768 | N/A |
| 12/31/2019 | 3,802 | 315 | -164 | 441 | N/A |
| 12/31/2018 | 3,279 | 211 | 378 | 542 | N/A |
| 12/31/2017 | 2,905 | 178 | N/A | 148 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: 605507's forecast earnings growth (22.5% per year) is above the savings rate (2.9%).
Bénéfices vs marché: 605507's earnings (22.5% per year) are forecast to grow faster than the CN market (21.9% per year).
Croissance élevée des bénéfices: 605507's earnings are expected to grow significantly over the next 3 years.
Chiffre d'affaires vs marché: 605507's revenue (13.9% per year) is forecast to grow faster than the CN market (13.4% per year).
Croissance élevée des revenus: 605507's revenue (13.9% per year) is forecast to grow slower than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: 605507's Return on Equity is forecast to be low in 3 years time (11.8%).